Movano (NASDAQ:MOVE – Get Free Report) and SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.
Volatility and Risk
Movano has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Movano and SOPHiA GENETICS, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Movano | 1 | 0 | 0 | 0 | 1.00 |
| SOPHiA GENETICS | 1 | 0 | 1 | 0 | 2.00 |
Profitability
This table compares Movano and SOPHiA GENETICS’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Movano | -4,302.13% | -359.83% | -203.15% |
| SOPHiA GENETICS | -40.99% | -30.69% | -17.39% |
Insider & Institutional Ownership
16.6% of Movano shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 21.1% of Movano shares are held by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Movano and SOPHiA GENETICS”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Movano | $1.01 million | 54.32 | -$23.73 million | ($4.07) | -1.61 |
| SOPHiA GENETICS | $65.17 million | 4.33 | -$62.49 million | ($0.44) | -9.50 |
Movano has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Movano, indicating that it is currently the more affordable of the two stocks.
Summary
SOPHiA GENETICS beats Movano on 10 of the 14 factors compared between the two stocks.
About Movano
Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. It develops System-on-a-Chip (SoC) for blood pressure or continuous glucose monitoring (CGM) systems. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
Receive News & Ratings for Movano Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Movano and related companies with MarketBeat.com's FREE daily email newsletter.
